Ailte I, Chauhan SK, Prasmickaite L, Bassarova AV, Poissonnier A, Feenstra M, Nyakas M, Johannessen B, Ryder T, Hermann R, Frich L, Holth A, Inderberg EM, Jespersen H, Flørenes VA, Kyte JA, Mælandsmo GM, Egeland EV (2026)
CD38^hiCD19^dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade
Front Oncol, 16, 1815008
DOI 10.3389/fonc.2026.1815008, PubMed 42158424

Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2026)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther (in press)
DOI 10.1016/j.ymthe.2026.09.027, PubMed 42800469

Ejder P, Jespersen H, Hernberg M, Ny L, Carneiro A, Ellegård S, Mattila K, Bagge RO, Fountoukidis G, Brandberg Y, Mandala M, O Carrigan B, Schilling B, Aranche A, Hamid O, Berglund A, Helgadottir H, Ullenhag G (2026)
Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma
BMC Cancer, 26 (1)
DOI 10.1186/s12885-026-15924-4, PubMed 41896823